BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dimairo M, Boote J, Julious SA, Nicholl JP, Todd S. Missing steps in a staircase: a qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials. Trials 2015;16:430. [PMID: 26416387 DOI: 10.1186/s13063-015-0958-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Wason JMS, Brocklehurst P, Yap C. When to keep it simple - adaptive designs are not always useful. BMC Med 2019;17:152. [PMID: 31370839 DOI: 10.1186/s12916-019-1391-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
2 Pickles T, Christensen R, Tam LS, Simon LS, Choy EH. Early phase and adaptive design clinical trials in rheumatoid arthritis: a systematic review of early phase trials. Rheumatol Adv Pract 2018;2:rky045. [PMID: 31431982 DOI: 10.1093/rap/rky045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Dimairo M, Julious SA, Todd S, Nicholl JP, Boote J. Cross-sector surveys assessing perceptions of key stakeholders towards barriers, concerns and facilitators to the appropriate use of adaptive designs in confirmatory trials. Trials 2015;16:585. [PMID: 26700741 DOI: 10.1186/s13063-015-1119-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
4 Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. Trials 2020;21:528. [PMID: 32546273 DOI: 10.1186/s13063-020-04334-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
5 Burnett T, Mozgunov P, Pallmann P, Villar SS, Wheeler GM, Jaki T. Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs. BMC Med 2020;18:352. [PMID: 33208155 DOI: 10.1186/s12916-020-01808-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Grayling MJ, Wheeler GM. A review of available software for adaptive clinical trial design. Clin Trials 2020;17:323-31. [PMID: 32063024 DOI: 10.1177/1740774520906398] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Antoniou M, Kolamunnage-Dona R, Jorgensen AL. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. J Pers Med 2017;7:E1. [PMID: 28125057 DOI: 10.3390/jpm7010001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
8 Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. BMJ 2020;369:m115. [PMID: 32554564 DOI: 10.1136/bmj.m115] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
9 Antoniou M, Jorgensen AL, Kolamunnage-Dona R. Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. PLoS One 2016;11:e0149803. [PMID: 26910238 DOI: 10.1371/journal.pone.0149803] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 8.2] [Reference Citation Analysis]
10 Bothwell LE, Avorn J, Khan NF, Kesselheim AS. Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov. BMJ Open 2018;8:e018320. [PMID: 29440155 DOI: 10.1136/bmjopen-2017-018320] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 12.3] [Reference Citation Analysis]
11 Flight L, Julious S, Brennan A, Todd S, Hind D. How can health economics be used in the design and analysis of adaptive clinical trials? A qualitative analysis. Trials 2020;21:252. [PMID: 32143728 DOI: 10.1186/s13063-020-4137-2] [Reference Citation Analysis]
12 Snowdon C. Qualitative and mixed methods research in trials. Trials 2015;16:558. [PMID: 26646545 DOI: 10.1186/s13063-015-1084-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
13 Love SB, Brown S, Weir CJ, Harbron C, Yap C, Gaschler-Markefski B, Matcham J, Caffrey L, McKevitt C, Clive S, Craddock C, Spicer J, Cornelius V. Embracing model-based designs for dose-finding trials. Br J Cancer 2017;117:332-9. [PMID: 28664918 DOI: 10.1038/bjc.2017.186] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
14 Metcalfe A, Gemperle Mannion E, Parsons H, Brown J, Parsons N, Fox J, Kearney R, Lawrence T, Bush H, McGowan K, Khan I, Mason J, Hutchinson C, Gates S, Stallard N, Underwood M, Drew S. Protocol for a randomised controlled trial of Subacromial spacer for Tears Affecting Rotator cuff Tendons: a Randomised, Efficient, Adaptive Clinical Trial in Surgery (START:REACTS). BMJ Open 2020;10:e036829. [PMID: 32444433 DOI: 10.1136/bmjopen-2020-036829] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Madani Kia T, Marshall JC, Murthy S. Stakeholder perspectives on adaptive clinical trials: a scoping review. Trials 2020;21:539. [PMID: 32552852 DOI: 10.1186/s13063-020-04466-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Flight L, Julious SA, Goodacre S. Can emergency medicine research benefit from adaptive design clinical trials? Emerg Med J 2017;34:243-8. [DOI: 10.1136/emermed-2016-206046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Dimairo M, Coates E, Pallmann P, Todd S, Julious SA, Jaki T, Wason J, Mander AP, Weir CJ, Koenig F, Walton MK, Biggs K, Nicholl J, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG. Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design. BMC Med 2018;16:210. [PMID: 30442137 DOI: 10.1186/s12916-018-1196-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
18 Wilson N, Biggs K, Bowden S, Brown J, Dimairo M, Flight L, Hall J, Hockaday A, Jaki T, Lowe R, Murphy C, Pallmann P, Pilling MA, Snowdon C, Sydes MR, Villar SS, Weir CJ, Welburn J, Yap C, Maier R, Hancock H, Wason JMS. Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project. BMC Med 2021;19:251. [PMID: 34696781 DOI: 10.1186/s12916-021-02124-z] [Reference Citation Analysis]
19 Mawocha SC, Fetters MD, Legocki LJ, Guetterman TC, Frederiksen S, Barsan WG, Lewis RJ, Berry DA, Meurer WJ. A conceptual model for the development process of confirmatory adaptive clinical trials within an emergency research network. Clin Trials 2017;14:246-54. [PMID: 28135827 DOI: 10.1177/1740774516688900] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, Holmes J, Mander AP, Odondi L, Sydes MR, Villar SS, Wason JMS, Weir CJ, Wheeler GM, Yap C, Jaki T. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med 2018;16:29. [PMID: 29490655 DOI: 10.1186/s12916-018-1017-7] [Cited by in Crossref: 162] [Cited by in F6Publishing: 143] [Article Influence: 40.5] [Reference Citation Analysis]
21 Hatfield I, Allison A, Flight L, Julious SA, Dimairo M. Adaptive designs undertaken in clinical research: a review of registered clinical trials. Trials 2016;17:150. [PMID: 26993469 DOI: 10.1186/s13063-016-1273-9] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 7.2] [Reference Citation Analysis]
22 Stevely A, Dimairo M, Todd S, Julious SA, Nicholl J, Hind D, Cooper CL. An Investigation of the Shortcomings of the CONSORT 2010 Statement for the Reporting of Group Sequential Randomised Controlled Trials: A Methodological Systematic Review. PLoS One 2015;10:e0141104. [PMID: 26528812 DOI: 10.1371/journal.pone.0141104] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
23 Zaki M, O'sullivan L, Devane D, Segurado R, Mcauliffe E. Factors influencing the statistical planning, design, conduct, analysis and reporting of trials in health care: A systematic review. Contemporary Clinical Trials Communications 2022. [DOI: 10.1016/j.conctc.2022.100897] [Reference Citation Analysis]
24 Curtin F, Heritier S. The role of adaptive trial designs in drug development. Expert Review of Clinical Pharmacology 2017;10:727-36. [DOI: 10.1080/17512433.2017.1321985] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]